Alkeon Capital Management
SANA icon

Alkeon Capital Management’s Sana Biotechnology SANA Stock Holding History

Alkeon Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-60,000
Closed -$1.18M – 189
2021
Q2 		$1.18M Hold
60,000
– – ﹤0.01% 177
2021
Q1 		$2.01M Buy
+60,000
New +$1.95M ﹤0.01% 169

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alkeon Capital Management's SANA Position: Q3 2021 in Review

Alkeon Capital Management sold out of Sana Biotechnology (SANA) in Q3 2021, closing a stake of 60,000 shares — an estimated $1.18M sold.

Alkeon Capital Management first reported a position in SANA in Q1 2021 and held it in 2 quarters. The position peaked at $2.01M in Q1 2021. 88 funds tracked by Wall St. Rank hold SANA as of Q3 2021.

  • Alkeon Capital Management reported no remaining Sana Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Alkeon Capital Management sold 60,000 Sana Biotechnology shares in Q3 2021, an estimated $1.18M.
  • Alkeon Capital Management first reported a position in Sana Biotechnology in Q1 2021 and held it in 2 quarters.
  • Alkeon Capital Management's Sana Biotechnology position peaked at $2.01M in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2021.

Based on Alkeon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.